Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
SRm300 CRISPR/Cas9 KO Plasmid (h): sc-403447
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SRm300 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the SRm300 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: SRm300 Antibody (C-9): sc-390315
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SRm300 CRISPR/Cas9 KO Plasmid (h) | sc-403447 | 20 µg | $397.00 |
Overview
SRRM2 encodes SRm300, a large serine/arginine-rich splicing cofactor that localizes to nuclear speckles and supports spliceosome assembly and pre-mRNA processing. SRm300 contributes to alternative splicing decisions and coordinates transcription–splicing coupling, influencing RNA maturation, mRNA export competence, and proteome diversity. Through these roles, SRRM2 affects pathways linked to cell-cycle regulation, DNA damage responses, and stress-adaptive gene expression programs. Dysregulation of SRRM2-dependent splicing networks has been associated with aberrant isoform usage observed in cancer and neurodevelopmental or neurodegenerative disease contexts, making it relevant for mechanistic studies of RNA processing.
SRm300 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SRRM2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SRRM2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SRRM2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SRm300 protein expression.
This CRISPR knockout system enables efficient generation of SRRM2-deficient cell models for investigation of SRm300 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting SRRM2 exon(s) critical for SRm300 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple SRRM2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by SRm300 CRISPR/Cas9 KO Plasmid (h) and SRm300 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the SRRM2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by SRm300 HDR Plasmid (h) and SRm300 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by SRRM2 homology arms to support homology-directed repair at defined SRRM2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.